Effectiveness of t-PA in acute ischemic stroke: Outcome relates to appropriateness
show the efficacy of tissue-type plasminogen activator (t-PA) in acute ischemic stroke. This was determined by a significant decrease in disability at 3 months. 5 Safety, judged by the excess risk of symptomatic hemorrhage, has been between 5% and 7%. 1, 4, 5 This efficacy and safety established the North American practice guidelines from the American Heart Association, 6 American Academy of Neurology, 7 and Canadian Stroke Consortium. 8 There is now pressure in Europe to adopt t-PA as the standard of care for ischemic stroke patients within a 3-hour time window.
Although "efficacy" is the product of a randomized clinical trial (i.e., can the intervention work under ideal circumstances?), "effectiveness" reflects the results of the intervention applied to average patients by practicing physicians in real-life circumstances. 9 We postulate that by adhering to the NINDS protocol, we could show the safety of t-PA in acute ischemic stroke and maintain the risk of symptomatic hemorrhage to a minimum in line with the accepted risk of the treatment. 1 We monitored our risk (symptomatic hemorrhage) and calculated the effectiveness as the number of patients needed to treat (NNT) to prevent one bad outcome. 10 Methods. We prospectively studied all patients presenting to the Foothills Hospital Medical Centre with acute stroke over a period of 30 months (April 1, 1996, to December 31, 1998) . All patients presenting within 3 hours with nonresolving hemiparesis of sudden onset had an immediate CT brain scan on a third-generation Toshiba Xpress SX helical scanner (Tokyo, Japan).
Acute stroke patients were admitted directly to a busy teaching hospital. Patients considered appropriate for thrombolysis were directly treated by a neurologist. All neurologists were familiar with the inclusion and exclusion criteria for thrombolytic therapy administration as outlined in the NINDS protocol. 1 After an emergency CT scan, patients fulfilling criteria were moved to the investigative stroke unit, where a baseline National Institutes of Health Stroke Scale (NIHSS) score was recorded. Patients with no signs of spontaneous improvement were eligible for treatment only after written consent had been obtained from the individual or a responsible family member. All patients were to be treated within 90 minutes of the CT scan.
Patients received 0.9 mg/kg of IV t-PA to a maximum of 90 mg based on either estimated or actual weight. Ten percent of the drug was given as a bolus, with the remainder of the dose infused over 1 hour. Both aspirin and heparin were contraindicated during the 24 hours after t-PA until no evidence of secondary hemorrhage was apparent at the follow-up CT scan. Follow-up NIHSS scores were performed 2 hours after infusion and subsequently at 24 hours (before the follow-up CT scan) and, for all those who survived, as outpatients at 3 months along with a modified Rankin score.
Data were collected during the first 24 hours for the demographic and pretreatment characteristics of the patients. Baseline characteristics and primary outcome variables (NIHSS, modified Rankin symptomatic hemorrhage) were compared between protocol patients and those who violated the protocol and with the results of the NINDS trial. Functional outcome was dichotomized into independence (modified Rankin 0 -2) and dependence (modified Rankin 3-5) and death. Significance was determined by either Fisher's exact test or chi-square analysis. The critical level for a two-sided test of each primary hypothesis was 0.05. Effectiveness is expressed as absolute risk reduction (ARR) in which we assume the baseline risk to be similar to the NINDS control group, and the NNT is calculated as 1/ARR. The number needed to harm was calculated assuming the baseline risk of primary intracranial hemorrhage was similar to the NINDS placebo group. Each value quotes the corresponding 95% CI.
Results. From April 1996 to the end of December 1998, 78 patients were treated at the Foothills Hospital with thrombolysis for acute stroke: 68 with IV t-PA and the other 10 intra-arterially. During this time, 2,350 patients presented to the regional healthcare hospitals with stroke of both hemorrhagic and ischemic types. Of 1,540 patients at Foothills Hospital, 350 presented within 3 hours of onset. The CT scan excluded 90 patients with primary hemorrhages and strokes presenting with a hemorrhagic conversion of the infarct. Other common reasons for exclusion from the Foothills Hospital protocol were the patients' symptoms actually exceeded the 3-hour time window, spontaneous resolution or improvement of symptoms, and an erroneous diagnosis. On three occasions, appropriate Most of our patients were treated in the afternoon and evening (on one occasion only was a patient treated between 12:00 AM and 7:00 AM). This probably is because time of onset was defined as the last time the patient was known to have been normal (i.e., the bedtime of patients with a waking deficit). The mean interval from emergency department arrival to treatment (door to needle time) was 100 minutes, 93 minutes for protocol patients.
Most patients (72%) showed early CT ischemic change. The percentage with CT evidence of infarction increased to 88% at 24 hours, underscoring the severity of the strokes in our cohort. Only four patients (6%) had extensive (i.e., involvement of greater than a third of the middle cerebral artery [MCA] distribution territory) 3 baseline lesions. Although these changes were not necessarily detected by the treating physician, they were readily apparent on subsequent review. Overall, 21 (31%) of 68 patients had some hemorrhagic conversion of the infarct, but only 6 (9%) had any symptoms of deterioration. Eleven patients died during the 3-month follow-up period.
There was one retrospective detection of subtle hemorrhagic conversion on the baseline scan. There were a total of 11 violations of the stated protocol, the details of which are summarized in table 2.
The risk of death and symptomatic hemorrhage was significantly increased in protocol violators. Three of these 6 symptomatic hemorrhages occurred in 11 nonprotocol patients (27%), whereas the remaining 3 occurred in the 57 protocol patients (5%) ( p Ͻ 0.05, Fisher's exact test). Six deaths occurred in those who had adhered to protocol (10%), whereas five deaths occurred in nonprotocol patients (46%) ( p Ͻ 0.01, chi-square). Only 1 (9%) of 11 nonprotocol patients regained independence, whereas 46% (n ϭ 26) of protocol patients made a full recovery and 67% (n ϭ 38) regained independence ( p Ͻ 0.02, chi-square) (table 3) .
The figure illustrates the follow-up neurologic and functional outcomes of the Calgary cohort of patients at 3 months in comparison with the NINDS study. To obtain Discussion. This article cannot comment on efficacy, as this study was not a randomized controlled trial (RCT), but it does show the feasibility of translating the results of clinical trials into routine clinical practice. 9 Efficacy established in a carefully controlled clinical trial may not be analogous to effectiveness in a day-to-day community setting, where a multitude of unpredictable variables results in deviations from the ideal situation of a trial. The Calgary cohort of stroke patients was collected outside the rigid constraints of a clinical trial, and the protocol violations are representative of the everyday reality of clinical practice. Our experience shows that t-PA administration for ischemic stroke in Ͻ3 hours is, in fact, feasible, safe, and effective with an NNT, when compared to the placebo group in the NINDS study, to produce one additional good outcome of six. This is shown in table 4.
Other evidence of the feasibility of t-PA administration for acute stroke comes from a cohort of patients in Houston and a retrospective review of treated patients from the t-PA Stroke Survey Group centered in Detroit. 12, 13 Both the University of Texas Health Sciences Center and the Henry Ford Hospital were participants in the original NINDS study 1 and continued to administer t-PA using the same study criteria after the study publication. Both were able to maintain similar complication rates and patient outcomes as achieved during the NINDS study. 12, 13 The Calgary cohort shows the feasibility of de novo introduction of this therapy into a community setting using existing resources, which are driven by a protocol to guide clinicians in the selection of appropri- ate patients. Learning to adhere to an established protocol is of extreme importance; in 10 of 11 of our patients in whom the protocol was violated, the consequences were severe, with either symptomatic hemorrhage, death, or dependence occurring to the patient. Community practice is driven, of course, by circumstance and is not bound by protocol. Enthusiasm to treat inevitably creates exceptions to established guidelines. Even when the NINDS guidelines are adhered to, the use of t-PA in acute ischemic stroke is not devoid of risk. The data now suggest that t-PA is safer than other thrombolytics (e.g., streptokinase). [14] [15] [16] In the NINDS study, treated patients performed better than placebo patients on all long-term outcome measures yet had a significantly elevated risk of symptomatic intracerebral hemorrhage (6.4% versus 0.64%). 1 The risk increased from 3.4% to 8.8% in ECASS II, although these patients were treated up to 6 hours. 4 The elderly and the severity of stroke, as judged by baseline NIHSS score, were identified by the NINDS study as increasing the risk of symptomatic hemorrhage. 1 Early ischemic changes on CT scan of greater than one-third of the MCA territory predicted an excess risk in ECASS I. 3 Hyperglycemia (blood glucose Ͼ12 mmol/L) may be an independent predictor of symptomatic hemorrhage. 17 In this study, two of the five symptomatic hemorrhages occurred in patients who presented with a homonymous hemianopia, raising the concern that the onset of visual field deficits cannot be accurately timed. Lesions in this region are associated with sensory and visual deficits in which time of onset may be inexact. Sudden onset of a motor deficit, ideally witnessed, provides the optimum assurance of an exact time of onset.
The concern of many physicians is whether the efficacy of treatment supported by evidence from RCTs can be applied to the totality of medical practice in terms of effectiveness and safety. Most neurologists, however, are willing to administer t-PA for appropriate stroke patients. 18 Of those neurologists who are unwilling to do so, most cite uncertainty and suggest the need for further studies. 19 The advent of interventional stroke neurology requires physician willingness, 20 experience with patient selection, and tutored CT scan interpretation. 21 Audit and safety monitoring will be essential components if the implementation of the first interventional therapy for acute ischemic stroke is to deliver what promises to be a major advance in stroke care. Article abstract-Background: The identification of lacunar infarcts before thrombolysis would make it possible either to exclude them from treatment or to show that they also may benefit from it. Objective: To determine whether clinical presentation or early CT findings of patients enrolled in the first European Cooperative Acute Stroke Study (ECASS I) trial would identify lacunar infarcts before treatment. Methods: Predictive values, sensitivity, specificity, and accuracy of clinical presentation as pure motor hemiparesis (PMH) or sensorimotor stroke (SMS) syndromes and of baseline CT findings in predicting lacunar infarcts were calculated in the ECASS I patients. Results: Of 514 patients, 44 placebo (17%) and 44 recombinant tissue plasminogen activator (rt-PA) (18%) patients had PMH/SMS involving at least two of three areas. Thirty-one placebo (12%) and 32 rt-PA (13%) patients had PMH/SMS involving three areas. The 7-day CT was compatible with a lacunar infarct in 32 placebo (12%) and 44 rt-PA (18%) patients. PMH/SMS involving at least two areas had a positive predictive value of 30% both in placebo and rt-PA patients, whereas positive predictive values of the involvement of three areas were 23% and 31%. Those of absence of early CT signs were 21% and 30%, and those of leukoaraiosis or previous lacunar infarcts were 21% and 23%. Positive predictive values of PMH/SMS involving at least two areas combined with absence of early CT signs were 36% in placebo and 33% in t-PA patients, and those of PMH/SMS plus leukoaraiosis or previous lacunes were 28% and 7%, respectively. Conclusions: In the ECASS I trial, lacunar infarcts were not recognizable on clinical grounds, and early CT findings, alone or in combination with the clinical picture, added poorly to the differential diagnosis. Key words: Lacunar infarcts-Thrombolysis. Thrombolysis in lacunar infarct patients is controversial because the underlying pathogenetic mechanisms could not be susceptible to pharmacologic reperfusion. 1 In contrast, the National Institute of Neurological Disorders and Stroke trial suggested that recombinant tissue plasminogen activator (rt-PA) may also be effective in patients with smallartery disease. 2 However, in both cases we wondered how lacunar infarcts can be correctly recognized when thrombolysis should be administered in the narrow time frame after stroke onset. 3, 4 In such an acute setting, it is difficult to perform the complex workup required for stroke subtype differentiation, 5 and one can only rely on clinical skill, at most supported by a CT scan. 6 A clinical presentation as a lacunar syndrome has been reported to correspond to lacunar infarcts in as many as 90% of patients, [7] [8] [9] [10] [11] suggesting that a lacunar syndrome may be synonymous with a lacunar infarct. mostly on patients seen 48 to 96 hours [8] [9] [10] [11] after stroke onset. In contrast, among patients with pure motor hemiparesis (PMH) and sensorimotor stroke (SMS) syndromes studied within 12 to 24 hours from stroke onset, only half had lacunar infarcts. [13] [14] [15] In studies that classified lacunar infarcts, taking into account, in addition to presentation as a lacunar syndrome, history of diabetes and hypertension as well as absence of cardiac sources of embolism and of ipsilateral carotid stenosis Ͼ50%, 16 the positive predictive value of the initial classification was 66%. 17 In lacunar infarct patients, leukoaraiosis, 18 previous lacunes, or both are reported more frequently and early CT signs of the infarct less frequently than in patients with nonlacunar infarcts. [19] [20] [21] [22] The ability of these variables to predict a lacunar infarct has not yet been investigated. The aim of this study was to evaluate whether in the first European Cooperative Acute Stroke Study (ECASS I) lacunar infarct patients could have been accurately identified on the basis of a clinical presentation as PMH/SMS or of CT findings before thrombolysis, and whether the combination of the clinical picture with baseline CT data could have improved the diagnosis.
Patients and methods. ECASS I was a multicenter trial that randomized 620 ischemic stroke patients to rt-PA or placebo within 4.2 Ϯ 1 hours of stroke onset. Clinical and CT criteria for patient selection are detailed elsewhere. 23 All patients were evaluated with the National Institute of Health Stroke Scale (NIHSS) as soon as possible and before treatment was started. 24 This scale consists of 14 items with 2 to 5 possible grades of deficit scored from 0 (no deficit) to 2, 3, or 4 (maximum deficit), depending on the item. According to this neurologic examination, patients who scored 0 in the items level of consciousness, gaze, visual field, limb ataxia, language, and extinction/ inattention and had a motor or sensorimotor deficit involving at least two of three areas (face, upper limb, lower limb) on one side of the body 8 were considered to have PMH/SMS. Patients without PMH/SMS were those with a score other than 0 in any of the above items, and those with a motor or sensorimotor deficit involving only one area. Moreover, because it has been suggested that the term lacunar syndrome should be used only when all three areas are involved, we performed an additional test identifying PMH/SMS using this definition. 25 The NIHSS was repeated after 24 hours to identify PMH/SMS patients who, by that time, had cortical signs and symptoms, and patients without PMH/SMS whose initial cortical signs and symptoms were no more evident after 24 hours.
In the baseline CT performed before treatment, we looked for early signs of stroke, which were part of the inclusion criteria in ECASS I, 23 and for leukoaraiosis 18 and previous lacunar infarcts.
The control CT performed after 7 Ϯ 1 days was used as the gold standard in identifying lacunar infarcts, defined as subcortical, sharply marginated areas of low attenuation with a diameter Յ1.5 cm. 26 Permanently negative CT scans in patients whose neurologic deficit lasted Ͼ24 hours were considered compatible with a diagnosis of lacunar infarct as well, irrespective of the clinical picture.
Statistical analysis. We used 2 ϫ 2 tables to calculate the positive and negative predictive values, sensitivity, specificity, and accuracy (with 95% CI) of the clinical presentation and baseline CT findings in predicting lacunar infarcts. We performed two analyses for clinical presentation: one considering PMH/SMS when at least two areas on one side of the body were involved, and the other when all three areas were affected. Finally, the analysis was applied to the combination of clinical presentation involving at least two areas with baseline CT findings. All analyses were performed separately in placebo and rt-PA patients.
Results.
Of the 620 patients enrolled in ECASS I, 106 (43 placebo and 63 rt-PA patients) were excluded from the present study because their baseline CT scan could not be evaluated for all the variables to be studied (n ϭ 13), they did not undergo the 7-day CT (n ϭ 79), or they lacked the 90-day modified Rankin scale evaluation (n ϭ 14).
Among the 514 patients studied, PMH/SMS with involvement of at least two areas was described in 44 placebo (17%) and 44 rt-PA (18%) patients ( p ϭ 0.8), whereas involvement of all three areas was detected in 31 (12%) and 32 (13%) patients ( p ϭ 0.7). Seven-day CT detected lacunar infarcts in 8 placebo (3%) and 7 rt-PA (3%) patients and was negative and from our definition also compatible with a lacunar lesion in an additional 24 placebo (9%) and 37 rt-PA (15%) patients.
Baseline CT findings of patients with lacunar and nonlacunar infarct at the 7-day CT are shown in table 1. In both placebo and rt-PA groups, early signs of the infarct were more frequently detected in nonlacunar than in lacunar patients ( p Ͻ 0.0001), whereas the frequency of leukoaraiosis and of previous lacunar infarcts was not significantly different among groups ( p ϭ 0.1). The predic- tive values, sensitivity, specificity, and accuracy of PMH/ SMS and those of baseline CT findings in predicting lacunar infarcts in placebo and rt-PA patients are shown in table 2. Both the clinical presentation and CT data had poor positive predictive values. Table 3 shows the predictivity of the combination of a clinical presentation as PMH/ SMS involving at least two areas with baseline CT findings. A lacunar infarct was observed in 36% of placebo and 33% of rt-PA PMH/SMS patients without early CT signs, as opposed to 26% of placebo and 7% of t-PA PMH/ SMS patients with leukoaraiosis or previous lacunes on the admission CT.
Signs and symptoms of "cortical" involvement of the 19 placebo and 31 rt-PA non-PMH/SMS lacunar patients are shown in table 4. At the 24-hour evaluation with the NIHSS, none of these signs and symptoms were any more evident in 6 placebo (32%) and 9 rt-PA (29%) patients. Table 4 also reports the "cortical" signs and symptoms detected at the 24-hour evaluation of 4 placebo (13%) and 5 rt-PA (16%) PMH/SMS nonlacunar patients. Had patients first been examined 24 hours after stroke onset, the predictive values, sensitivity, specificity, and accuracy of a clinical presentation as PMH/SMS would have been those reported in table 5.
Discussion. This study shows that in the ECASS I patients, a clinical presentation as PMH/SMS within a few hours of stroke onset corresponded to lacunar infarcts in less than one-third of patients. This confirms the results of previous studies on PMH/SMS patients first seen within 12 to 24 hours after stroke onset, suggesting that the earlier stroke patients are seen, the worse the diagnosis. [13] [14] [15] 17 However, the multicenter structure of the ECASS I study may have led to a somewhat heterogeneous clinical evaluation of patients, explaining at least in part the poor clinical diagnosis of lacunar infarcts. Another caveat of this study is that the choice to consider all negative 7-day CT scans as lacunar infarcts, irrespective of the clinical picture, might be debatable, particularly when applied to patients receiving rt-PA, which might have prevented the progression of brain ischemia toward infarct. The observation that permanently negative CT scans in rt-PA patients were 15% compared with 9% in placebo patients would confirm this objection. However, had we considered non-PMH/SMS patients with permanently negative CT as having nonlacunar infarct, for both placebo and rt-PA patients the negative predictive value would have increased to 98%, the sensitivity to 72%, and the specificity to 87%, but the positive predictive value of PMH/SMS would not However, the hypothesis of a less thorough neurologic examination, conceivable particularly in an acute setting, can be discarded in ECASS I because the NIHSS-guided physicians performed a neurologic evaluation that included higher functions. In fact, not only dysphasia and neglect but also other "cortical" symptoms such as visual field deficits, gaze palsy, and impaired level of consciousness were described at admission in non-PMH/SMS lacunar patients. These "cortical" symptoms were also detected at the 24-hour neurologic examination in PMH/SMS nonlacunar patients.
"Cortical" symptoms were described in patients with small cerebral infarctions and were attributed to a subcortico-cortical disconnection producing a functional depression in a structurally intact cerebral region. 27 Further, in patients studied in the very first days, a profound metabolic depression over the unaffected hemisphere was described that diminished over the next days, together with its clinical correlate. 28 These phenomena may explain the more severe and complex expression of neurologic deficit in the acute phase of a lacunar infarct. Accordingly, approximately one-third of both placebo and rt-PA non-PMH/SMS lacunar patients had no "cortical" symptoms at the 24-hour neurologic examination. However, in PMH/SMS nonlacunar patients, a progression of the infarct seems to be the most tenable explanation, as suggested by the detection of "cortical" symptoms in 15% of them at the 24-hour neurologic examination. 29 However, misdiagnosis occurs, and it seems that in the acute setting, a clinical presentation as a lacunar syndrome is not predictive of small deep lesions. [13] [14] [15] 17 This contradicts previous statements that may be tenable in subsequent phases of the clinical course. 30 By adopting the so-called lacunar syndromes as an exclusion criteria in pharmacologic trials, there is the risk of excluding from treatment a sizable portion of nonlacunar patients.
Following the observation that patients with leukoaraiosis or lacunar infarcts tend to have new lacunar strokes, [19] [20] [21] we decided to evaluate whether baseline CT findings might identify the stroke caus- * Neurologic examination at hospital admission in non-pure motor hemiparesis (PMH)/sensorimotor stroke (SMS) lacunar patients and at 24 hours in PMH/SMS nonlacunar patients. ing patient hospitalization as a lacunar event. In our series, leukoaraiosis and previous lacunes were poor predictors of lacunar infarcts. However, the absence of early CT signs of the infarct proved to be a better indicator and a far more sensitive variable. 22 The notion that early CT signs are caused by the increase in water content of brain tissue, 31 which in turn depends on the depth 32 and extent of ischemia, may well explain why early CT signs are generally invisible in strokes from small-artery disease. 22 Finally, the absence of early CT signs, combined with PMH/ SMS presentation involving at least two areas, corresponded to a lacunar infarct in 36% of placebo and 33% of rt-PA patients. This still represents an unsatisfying predictive power, although it is better than that of each of the variables alone.
